Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Treatment Outlook (2022 to 2032)

In 2021, the Global Inflammatory Bowel Disease Treatment market was worth around USD 19.3 Billion.

With the increasing expenditure incurred on Inflammatory Bowel Disease Treatment worldwide, the market is expected to reach a worth of about USD 35.1 Billion by the end of 2032, with a projected CAGR of 5.7% from 2022 to 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment Market experienced a growth of 4.7%.

Attributes	Details
Global Inflammatory Bowel Disease Treatment Market Size (2021)	USD 19.3 Billion
Global Inflammatory Bowel Disease Treatment Market Size (2022)	USD 20.2 Billion
Projected Market Value (2032)	USD 35.1 Billion
Global Market Growth Rate (2022 to 2032)	5.7% CAGR
United States Growth Rate (2022 to 2032)	6.4% CAGR
Share of Top 5 Countries	61%
Key Companies Profiled	AbbVie Inc.; Biogen; Johnson & Johnson Services, Inc.; Amgen Inc.; UCB S.A.; Novartis AG; Takeda Pharmaceutical Company Limited; Merck & Co., Inc.; Pfizer Inc.; Eli Lilly

Inflammatory Bowel Disease can occur at any age, although the disease is most common in adolescents and adults between the ages of 15 and 35. Diet and Stress do not cause inflammatory bowel disease but they can worsen the conditions. According to some recent research, hereditary, genetic, and environmental factors contribute to the disease’s development.

According to a 2019 estimate from the Crohn's and Colitis Foundation, 1.6 million Americans have inflammatory bowel disease. In addition, the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) estimates that in 2020, there were about 3.4 million people in Europe who have IBD of some kind. IBD is affecting more and more people, which increases the need for efficient treatment solutions.

In the forthcoming years, the Inflammatory Bowel Disease Treatment market is expected to expand due to the rising use of biologics for the treatment of inflammatory bowel disease and the release of potent pipeline medications including Risankizumab, Ustekinumab, Tofacitinib, and upadacitinib.

In the upcoming years, the Inflammatory Bowel Disease Treatment market expansion is expected to be boosted by an increase in initiatives taken by various organizations to address the difficulties in the creation of novel therapies.

For instance, the Crohn's and Colitis Foundation published a five-year plan in May 2019 to identify gaps in IBD research, development, and care. Additionally, the European Chronic Disease Alliance has made a lot of efforts to enhance the quality of life for people with inflammatory bowel disease.

Region-wise Insights

Which region holds the largest market for Inflammatory Bowel Disease Treatment?

North America holds the largest Inflammatory Bowel Disease Treatment market. In 2021, North America contributed to around 40% of the global revenue. As of 2019, there were 730 clinical trials for IBD, including drug development, observational studies, and others, according to the USA National Library of Medicine. Of these, 268 clinical trials were carried out only in the USA.

A substantial portion of the IBD market in North America is held by Canada. The number of Canadians with IBD is almost around 300,000. It is anticipated that treating Canadians with IBD will cost USD 1.28 Billion each year. The Quebec government launched a biosimilars initiative in 2021, according to announcements made by the minister of health and social services, Christian Dubé, patients will transition from original biologic medications to their biosimilar equivalents.

Besides, Asia-Pacific accounts for a promising Inflammatory Bowel Disease Treatment market. This is mainly due to the growing access to healthcare, increasing per capita medical expenditure, and rise in the number of patients with inflammatory bowel disease. The commonness of inflammatory bowel disease is higher in Asian countries including India, China, and Japan.

With 1.5 million IBD patients in 2020, India surpassed the USA as the nation with the most IBD patients. In India, only 3% of patients use biologics, a much lower percentage than in Western nations. Infliximab and Adalimumab, two biologics, have IBD approval in India. Since June 2020, Vedolizumab has also been approved.

A significant portion of all cases of inflammatory bowel disease is seen in Japan. Only infliximab and Adalimumab are approved in Japan for the treatment of both UC and CD, and the USA Food and Drug Administration approved five biological drugs for the treatment of IBD in 2016.

Country-wise Insights

USA Inflammatory Bowel Disease Treatment Market

The USA has the largest market for Inflammatory Bowel Disease Treatment, which is projected to reach a valuation of USD 13.6 Billion by 2032. From 2017 to 2021, the Inflammatory Bowel Disease Treatment market in the USA grew at a CAGR of 4.7% and is expected to experience a CAGR of 6.4% in the next ten years. Between 2022 and 2032, the USA is expected to be a market with a USD 6.2 Billion absolute dollar opportunity.

According to the Crohn's and Colitis Foundation (CCFA), the number of new cases of Inflammatory Bowel Disease reported in the USA each year exceeds 70,000. Infliximab, Adalimumab, Certolizumab Pegol, and Golimumab are the four anti-TNF medications that have been authorized for the treatment of IBD in the USA. Two anti-integrin biologics, Natalizumab and Vedolizumab, have been licensed for the treatment of IBD, and biosimilars for both anti-TNF medications have been created. In the USA, the biologic Stekinumab, which inhibits the cytokines IL-12 and IL-23, has been licensed for the treatment of Crohn's disease.

China Inflammatory Bowel Disease Treatment Market

In 2021, China was the second-largest Inflammatory Bowel Disease Treatment Market after the USA. The market in the country is expected to reach a valuation of USD 4.2 Billion by 2032. From the year 2017 to 2021 China’s Inflammatory Bowel Disease Treatment Market experienced a CAGR of 5.5% and is projected to see a similar CAGR of 6.8% in the next ten years. By 2032, China is expected to be an absolute dollar opportunity of USD 2 Billion.

A huge portion of the population smokes in China owing to the country's rising industrialization and evolving lifestyle. The World Bank estimates that in 2016, 48.4% of all male smokers were in China. Smoking has a negative impact on both the small and large intestines, which raises the prevalence of IBD treatment in China.

Reistone Biopharma Co. Ltd., a Chinese biopharmaceutical company in the clinical stages, reported positive findings from a phase II clinical trial that assessed the safety and effectiveness of its drug candidate, SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, for the treatment of moderate-to-severe ulcerative colitis. The trials are being carried out in various locations, such as China, the USA, and other countries. The company was considering launching a phase III clinical trial in 2021.

United Kingdom Inflammatory Bowel Disease Treatment Market

The market in the United Kingdom is expected to grow from USD 842.5 Million in 2017 to reach a valuation of USD 1.4 Billion by 2032. During the next 10 years, the market in the country is expected to grow at a CAGR of 4.6% to gross an absolute dollar opportunity of USD 509 Million during the forecast period.

Category-wise Insights

Which Type of Inflammatory Bowel Disease Treatment is generating the most revenue in the Market?

Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% from 2022 to 2032.

In 2021, revenue from Crohn's Disease treatment outscored the management of Crohn's Disease 2021 with a market share close to 60 percent. That with the increase in cases has helped to authorize the use of more and more biologics in the marketplace for the treatment of Inflammatory Bowel Disease.

According to Crohn’s and Colitis Foundation, around 25% of patients with Crohn's disease in the USA are prescribed biologics. Moreover, the popularity of Crohn’s disease is about 319 per 100,000 population in North America, while in Europe it is about 322 per 100,000 population.

Competitive Landscape

The Inflammatory Bowel Disease Treatment market is moderately competitive and has numerous players. The key companies operating in the Inflammatory Bowel Disease Treatment Market are AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc., and Eli Lilly. To secure a dominating position in the market making key players are focusing on introducing new products through collaborations and partnerships.

Some of the recent developments by the key providers of Inflammatory Bowel Disease Treatment are as follows:

• In May 2022, The IBD NutriCare App was released by the Indian Council of Medical Research (ICMR) to enhance patient care for inflammatory bowel disease (IBD). This software offers real-time data that notifies the dietician or nutritionist of concerns with inaccurate information, enabling prompt nutritional changes.
• In March 2022, The USA Drug and Food Administration authorized RINVOQ (Upadacitinib) for the treatment of people with moderately to highly active Ulcerative Colitis, according to a statement from AbbVie Inc.
• In May 2021, the USA Food and Drug Administration have authorized Zeposia (ozanimod) 0.92 mg for the treatment of individuals with moderately to highly active Ulcerative Colitis, according to Bristol-Myers Squibb Company.
• In March 2021, the monoclonal antibody Lucent-1, developed by the American pharmaceutical company Eli Lilly and Company is being studied in phase III for the treatment of moderate to severe ulcerative colitis.
• In March 2020, Entyvio (vedolizumab), a drug manufactured by the Japanese multinational pharmaceutical corporation Takeda Pharmaceutical Co. Ltd., has been given approval in China by the National Medical Products Administration (NMPA). For people in China who were intolerant of or sensitive to conventional therapy or tumor necrosis factor-alpha (TNF) inhibitors, it is a gut selective biologic approved to treat moderate to severe ulcerative colitis and Crohn's disease.

Key Segments Covered in Inflammatory Bowel Disease Treatment Market Survey

Inflammatory Bowel Disease Treatment Market by Type:

• Crohn’s Disease
• Ulcerative Colitis

Inflammatory Bowel Disease Treatment Market by Drug Case:

• Amino salicylates
• Corticosteroids
• TNF inhibitors
• IL inhibitors
• Anti-integrin
• JAK inhibitors
• Other Drug Classes

Inflammatory Bowel Disease Treatment Market by Route of Administration:

• Oral
• Injectable

Inflammatory Bowel Disease Treatment Market by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Inflammatory Bowel Disease Treatment Market by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa(MEA)
• Latin America

Frequently Asked Questions

How much is the global Inflammatory Bowel Disease Treatment Market currently worth?

The global Inflammatory Bowel Disease Treatment Market was valued at USD 20.2 Billion in 2022 and is expected to be a USD 14.9 Billion absolute dollar opportunity by 2032.

What is the Inflammatory Bowel Disease Treatment Market Forecast through 2032?

Over the projected period, the Inflammatory Bowel Disease Treatment Market is expected to increase at a CAGR of 5.7%, reaching a value of USD 35.1 Billion by 2032.

At what rate did demand for Inflammatory Bowel Disease Treatment increase over the past few years?

The Inflammatory Bowel Disease Treatment Market expanded at a CAGR of 4.7% from 2017 through 2021.

Which Inflammatory Bowel Disease is seen to be the most common among patients?

Crohn’s Disease is seen to be the most common Inflammatory Bowel Disease. Revenue through the treatment of Crohn’s Disease expanded at a CAGR of 5% from 2017 to 2021 and is projected to grow at a CAGR of 6% by 2032.

Who are the key players shaping the Inflammatory Bowel Disease Treatment Industry?

AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., UCB S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and Pfizer Inc., are some of the key players in the Inflammatory Bowel Disease Treatment Industry.

Who are the top 5 countries driving the highest Inflammatory Bowel Disease Treatment?

The USA, United Kingdom, China, Japan, and South Korea are expected to drive the most Inflammatory Bowel Disease Treatment.